Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

Contributed by: Business Wire

Logo

Tags

Professional Services

Health

Other Health

Finance

Clinical Trials

Pharmaceutical

Biotechnology

Amolyt Pharma

More Like This

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

Edward Kliphuis, Partner, Sofinnova Digital Medicine Strategy and Simon Turner, Partner, Sofinnova Digital Medicine Strategy (Photo: Sofinnova Partners)

Sofinnova Partners Raises $200M Digital Medicine Fund

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups

Sofinnova.AI (Photo: Sofinnova)

Sofinnova Partners Unveils Sofinnova.AI: A Cutting-edge Artificial Intelligence Platform Set to Transform Its Life Sciences Investment Practice

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

PR Newswire associated0

Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies